H
idradenitis suppurativa is a chronic condition characterized by recurrent inflammation and infection of skin containing apocrine glands. Patients develop erythema, inflammatory nodules, abscesses, discharging sinus tracts, and scarring. The condition most commonly affects the axilla and groin but may affect other intertriginous areas such as the inframammary fold. The distribution tends to be symmetrical. This is a common condition, with prevalence estimated to be 1 percent, and it is approximately three times more common in female patients than in male patients. 1 Onset tends to be insidious following puberty, and prevalence diminishes after menopause. There is a high prevalence of smoking and obesity among sufferers, 1 and it is likely that there is a genetic influence. 2 There has been no proven hormonal link.
The disease affects skin containing apocrine glands, which are the remnants of odor-producing glands and which are concentrated in the axilla and groin. Apocrine glands have coiled secretory components in the deep dermis or subcutaneous tissue that drain through long excretory ducts into hair follicles. The condition was thought to be primarily a disorder of apocrine glands, but it has since been shown that the initial event is hair follicle occlusion by keratinous plugging 3 that leads to apocrine gland stasis, dilation, inflammation, and eventual rupture into the surrounding subcutaneous fat. Bacterial infection contributes to pathogenesis but is likely to be a secondary phenomenon, as cultures from lesions are frequently sterile and antibiotics are not curative. In severe disease, various pathogens can be present, including coagulase-negative Staphylococcus, Staphylococcus aureus, and Propionibacterium. 4 Early disease findings are erythema and inflammatory nodules, which later form abscesses and chronic discharging sinuses. There is progressive destruction of normal skin leading to fibrosis and contracture. A staging system for the condition was described by Hurley ( Table 1 ). The condition has been shown to have a higher impact on quality of life than other chronic skin diseases such as acne, atopic dermatitis, and psoriasis. 5 The treatment of hidradenitis suppurativa has proven to be difficult and unsatisfactory. Treatment is tailored to the site and extent of the disease. For early disease, topical or systemic antibiotics can improve symptoms, although adverse side effects may complicate long-term therapy, and there is usually disease recurrence on discontinuation of treatment. 6 Trials of antiandrogens, 7 retinoids, 8 immunosuppression, 9 -11 and botulinum toxin 12 have yielded mixed results. For severe ongoing disease, radical surgical excision of all skin containing apocrine glands in the affected area may be indicated. The resultant wound may be left to heal by secondary intention or closed by a split-thickness skin graft or flap reconstruction. However, surgery is associated with significant complications such as wound infection, delayed healing, skin graft or flap failure, scar contracture, and poor cosmetic outcome. Furthermore, despite performing radical excision, there is still a significant risk of recurrence that varies with the disease site, being low after axillary excision (3 percent) but high after inguinoperineal (37 percent) and inframammary (50 percent) excision. 13 Therefore, radical surgery appears to be effective in eradicating hidradenitis suppurativa of the axilla but is less satisfactory for inguinoperineal and inframammary disease.
There has been limited research to date on the use of light and laser in treatment of hidradenitis suppurativa. Gold et al.
14 published a case series of four patients treated with photodynamic therapy. After three to four treatments at 1-to 2-week intervals, clearance was noted in 75 to 100 percent of patients at 3 months, but no specific outcome measures were stated. Strauss et al. 15 published a conflicting report on four patients treated with photodynamic therapy, reporting that two patients withdrew from the study and two patients reported worsening of symptoms at 8 weeks. Lapins et al. 16 treated 31 patients with hidradenitis suppurativa using an ablative carbon dioxide laser, and at 4 weeks, 22 of the 24 patients had no recurrence.
Intense pulsed light therapy uses high-energy broad-spectrum light. 17 It is noninvasive, causes minimal discomfort, and has a very low risk of side effects such as blistering or pigmentation changes. No downtime is usually required for recovery after treatment. Current applications include hair removal and the treatment of acne vulgaris, 18 which has a pathogenesis similar to hidradenitis suppurativa. Intense pulsed light causes thermal damage to hair follicles. As hidradenitis suppurativa is known to evolve from follicular occlusion, we postulated that it would be effective in treating the glandular stasis and inflammation that characterize this condition. Intense pulsed light also has an antibacterial effect through the excitation of bacterial porphyrins that leads to the generation of reactive oxygen species and cell death.
PATIENTS AND METHODS
Ethical approval was obtained from the local research ethics committee, and a total of 18 patients were recruited for this study. The inclusion criteria were adults with Hurley stage II or III hidradenitis suppurativa with bilateral axillary, groin, or inframammary disease. Patients must not have been using topical or systemic therapy for 2 weeks before the first treatment.
Patients were randomized to treatment of one axilla, groin, or inframammary area with intense pulsed light therapy two times per week for 4 weeks (420 nm; fluence, 7 to 10 J/cm 2 ; pulse width, 30 to 50 msec) using a Harmony Laser Patients were assessed immediately before and after treatment and then at 3, 6, and 12 months. Both the treatment and control sites were assessed before and after treatment to detect any difference in disease severity at the sites.
The response to treatment was measured using a validated hidradenitis suppurativa examination scoring system described by Sartorius et al. 19 ( Table 2) , with a higher score indicating more severe disease at that site. A blinded nontreating plastic surgeon examined the treatment and control sites at each assessment visit. Standardized clinical photographs of the treatment and control sites were taken before and after treatment and then assessed by two plastic surgeons blinded to which side was treated. Patients rated their satisfaction with the treatment on a Likert scale as being worse, unchanged, fair, good, or excellent.
Statistical Analysis
A longitudinal regression analysis using the generalized estimating equation 20 was used to analyze changes in the examination scores before treatment; immediately after treatment; and at 3, 6, and 12 months. All anatomical sites (i.e., axilla, groin, and inframammary) treated were grouped together for the purpose of the analysis because of the small number of patients included in this study.
An interrater reliability analysis using the kappa statistic was performed to determine the consistency between the blinded experts assessing the clinical photographs. Kappa values range from 0 to 1; a value close to 1 indicates concordance between assessors and high reliability, and a value close to 0 suggests that agreement between raters may be attributable to chance alone.
RESULTS
Eighteen patients were recruited for the study. The mean age was 34 years (range, 17 to 50 years), and there was a higher proportion of women (n ϭ 15) than men (n ϭ 3). A high proportion of the patients were smokers (n ϭ 12). The distribution of anatomical sites was 12 patients with axillary disease, four patients with groin disease, and two patients with inframammary disease. One patient withdrew after the first treatment, which she found to be painful, and was not included in the analysis. Seventeen patients completed the full course of treatment.
There was no significant difference in disease severity at the control and treatment sites before treatment commenced (p ϭ 0.31, paired t test). Compared with the baseline examination scores recorded before treatment, the change in the hidradenitis suppurativa examination score averaged for all treated sites was -55 percent immediately after treatment, -56 percent at 3 months after treatment, -44 percent at 6 months after treatment, and -33 percent at 12 months after treatment, representing an improvement in the examination score following treatment. The percentage change in the examination score averaged for all control sites was 12 percent immediately after treatment, -10 percent at 3 months after treatment, -10 percent at 6 months after treatment, and 3 percent at 12 months after treatment (Figs. 1 through 4) .
A longitudinal regression analysis using the generalized estimating equation was carried out using all valid data for the 17 patients. There was a significant reduction in the hidradenitis suppurativa examination score on the treated side (p Ͻ 0.001).There was a significant difference between the treated and control sides in the pattern of change in the examination score over time (p Ͻ 0.001). There was little change on the control side; however, the treated side showed a significant reduction in the examination score after treatment that was maintained at 12 months (p ϭ 0.001).
There was a high level of patient satisfaction with treatment, with one patient reporting the disease had cleared, two patients reporting excellent results, 10 patients reporting good results, and four patients reporting fair results on the treated side. The majority of patients reported disease on the control side as unchanged (15 patients), with one patient reporting slight Volume 128, Number 2 • Treatment of Hidradenitis Suppurativa improvement and one patient reporting a slight deterioration. Standardized clinical photographs of the treatment and control sides were taken before and after treatment and assessed by two plastic surgeons blinded to which side was treated. The experts detected an improvement in the signs of hidradenitis suppurativa on the treated side but no change on the control side, with high interrater reliability (kappa ϭ 0.79, p Ͻ 0.001).
DISCUSSION
The results of this small study suggest that intense pulsed light may be an effective treatment modality for hidradenitis suppurativa. We noted a statistically significant improvement in the examination score following treatment that was maintained at 12 months, indicating that intense pulsed light treated existing lesions and prevented recurrence. There was no significant concurrent change in disease activity at the untreated control sites. The findings on clinical examination were confirmed by independent assessment of clinical photographs. Patients reported a high level of satisfaction with the treatment.
There was a possible trend toward recurrence at 12 months. This indicates that further courses of intense pulsed light treatment may be required over time. In this study, patients underwent intense pulsed light (420 nm; fluence, 7 to 10 J/cm 2 ; pulse width, 30 to 50 msec) with Harmony Laser treatment two times per week for 4 weeks. Further research may focus on the optimal intense pulsed light settings and treatment protocol.
Intense pulsed light uses high-energy broadspectrum light. 17 Current applications include hair removal and the treatment of acne vulgaris, Plastic and Reconstructive Surgery • August 2011 which has a pathogenesis similar to that of hidradenitis suppurativa. Intense pulsed light causes thermal damage to hair follicles, and because hidradenitis suppurativa is known to evolve from follicular occlusion, we postulated that this could be effective in treating the glandular stasis and inflammation that characterize this condition.
Intense pulsed light has an antibacterial effect through the excitation of bacterial porphyrins, which leads to the generation of reactive oxygen species and cell death.
There is limited research on the molecular mechanism of action of intense pulsed light. Recent studies that investigated the mechanism of action of intense pulsed light in skin rejuvenation 21, 22 demonstrated that intense pulsed light alters the levels of superoxide dismutase, matrix metalloproteinase, and transforming growth factor-␤ through regulation of gene expression. A similar molecular mechanism may account for the efficacy of intense pulsed light in hidradenitis suppurativa through modulation of the local inflammatory response. Further pathologic and molecular studies are required to determine the mechanism of action of intense pulsed light in hidradenitis suppurativa.
Intense pulsed light is noninvasive and usually causes minimal discomfort. It has a very low risk of complications such as blistering or pigmentation changes, and in our study there were no complications. Unlike surgery, there is usually no downtime following treatment. On the basis of these results, we suggest that intense pulsed light may be an effective treatment for hidradenitis and could be added to the treatments used for this condition. It could reduce the need for antibiotics. Furthermore, we believe that intense pulsed light is a noninvasive option for patients wanting to avoid surgery, and that it has a particular role in the treatment of groin and inframammary disease where surgical excision may be disfiguring and is associated with a high risk of recurrence.
CONCLUSIONS
Intense pulsed light is a promising new treatment for hidradenitis suppurativa. It is associated with minimal discomfort and a low risk of side effects. Unlike surgery, there is usually no downtime following treatment. Our results demonstrate a reduction in the severity of hidradenitis suppurativa following treatment and a high level of patient satisfaction.
Intense pulsed light could be a treatment option for hidradenitis suppurativa sufferers, particularly those keen on avoiding surgery and those with groin and inframammary disease where the results of surgery are disappointing. Further studies are required to confirm the efficacy and mech- 
